Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester

摘要

Our dermatology unit recently treated two patients, both with unplanned pregnancies while on ustekinumab for psoriasis. ER, a 54-year-old woman with a history of recalcitrant psoriasis received her last dose of ustekinumab at 4 weeks' gestation; having received a total of four doses. She had an uneventful pregnancy and delivered a healthy, full-term female infant with no complications. BF, a 21-year-old woman who had previously failed conventional therapies as well as a trial of etanercept was found to be unexpectedly 4 weeks pregnant while receiving ustekinumab. She had received a total of five doses; the last at 2 weeks' gestation. She experienced a significant flare of psoriasis at 34 weeks' gestation but had an otherwise uncomplicated pregnancy. The delivery of a healthy, full-term baby ensued with no complications.